

Cambridge University Hospitals

Investigating Gut Hormone Levels in Human Health and Disease "GutHHD"

Protocol A – Fasting And Post Meal One Page reference sheet – Patients Prescribed Gut Peptide Agonist

Thank you for your interest in the study. The study aims to assess how gut hormones level in human health and disease. The aim is that results from this will aid in development of treatments and diagnostic tests for metabolic and gastrointestinal diseases.

Eligibility

You are eligible to take part if you aged between 18 and 75 and if you prescribed a gut peptide agonist including GLP-1 agonist (eg liraglutide, semaglutide, or combined GLP-1/GIP agonist tirzepatide) or GLP-2 agonist (eg teduglutide) as part of your standard clinical care.

Study Overview

The study involves two visits lasting up to 6-7 hours. You will arrive fasted and then have blood samples taken for up to 4 hours whilst continuing to fast. You will then have a controlled liquid meal or an oral glucose drink and have further blood tests for up to a further 2 hours. You will then be free to eat and drink as normal. You will then attend for a second visit after at least 14 days of gut peptide agonist therapy with your regular doctor.

You will receive travel reimbursement of up to £50 per visit and a fee of £50 for taking part. Study days take place at **Translational Research Facility, Addenbrooke's hospital.**

Participants contact research team after seeing advertisement Formal consent gained to take part in study (either in virtual screening appointment or on study day). Checks made against inclusion and exclusion criteria

Start bowel habit diary up to 7 days prior to first study day. Arrive to take part in

first study day following overnight fast. Anthropometric measures taken Cannula inserted and first blood sample taken alongside screening blood test. Blood samples taken every 15 mins for up to 4 hours.

Ensure Meal or Oral Glucose Given

Further blood samples taken for up to 2 hours

Cannula removed

Participant started on gut peptide agonist by their direct clinical care team. Return for visit of same design at least 2 weeks later after starting therapy After visit 2 discharged from study.

Contact

If you have any questions, would like to take part or for more information contact:

cuh.guthormonestudies@nhs.net